A haemochromatosis-causing HFE mutation is associated with SARS-CoV-2 susceptibility in the Czech population

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F22%3AN0000055" target="_blank" >RIV/00064190:_____/22:N0000055 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00130381 RIV/00216208:11110/23:10452023 RIV/00216208:11120/23:43924470 RIV/00064190:_____/23:10000992 a 2 dalších

Výsledek na webu

<a href="https://doi.org/10.1016/j.cca.2022.12.025" target="_blank" >https://doi.org/10.1016/j.cca.2022.12.025</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cca.2022.12.025" target="_blank" >10.1016/j.cca.2022.12.025</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A haemochromatosis-causing HFE mutation is associated with SARS-CoV-2 susceptibility in the Czech population

Popis výsledku v původním jazyce

Background: Coronavirus disease (COVID-19), which is caused by the SARS-CoV-2 virus, has become a global pandemic. While susceptibility to COVID-19 is subject to several external factors, including hypertension, BMI, and the presence of diabetes, it is also genetically determined to a significant extent. Infectious agents require iron (Fe) for proper functioning. Carriers of mutations resulting in increased iron concentrations are understood to be at increased risk of COVID-19.Methods: We examined HFE genotypes associated with hereditary haemochromatosis (rs1800562 and rs1799945 SNPs) in 617 COVID-19 patients (166 asymptomatic, 246 symptomatic and 205 hospitalised survivors) and 2 559 population-based controls.Results: We found a higher frequency of the minor allele (Tyr282) of the rs1800562 polymorphism (P < 0.002) in patients compared to controls (8.5 % vs 5.5 %). Non-carriers of the minor allele were protected against SARS-Cov-2 infection (OR, 95 %CI; 0.59, 0.42-0.82). The frequency of minor allele carriers was almost identical across asymptomatic, symptomatic, and hospitalised survivors. The rs1799945 variant did not affect disease severity and its occurrence was almost identical in patients and controls (P between 0.58 and 0.84).Conclusions: In conclusion, our results indicate that presence of the rs1800562 minor allele, which is associated with hereditary haemochromatosis (thus increased levels of plasma Fe), increases susceptibility to SARS-CoV-2.

Název v anglickém jazyce

A haemochromatosis-causing HFE mutation is associated with SARS-CoV-2 susceptibility in the Czech population

Popis výsledku anglicky

Background: Coronavirus disease (COVID-19), which is caused by the SARS-CoV-2 virus, has become a global pandemic. While susceptibility to COVID-19 is subject to several external factors, including hypertension, BMI, and the presence of diabetes, it is also genetically determined to a significant extent. Infectious agents require iron (Fe) for proper functioning. Carriers of mutations resulting in increased iron concentrations are understood to be at increased risk of COVID-19.Methods: We examined HFE genotypes associated with hereditary haemochromatosis (rs1800562 and rs1799945 SNPs) in 617 COVID-19 patients (166 asymptomatic, 246 symptomatic and 205 hospitalised survivors) and 2 559 population-based controls.Results: We found a higher frequency of the minor allele (Tyr282) of the rs1800562 polymorphism (P < 0.002) in patients compared to controls (8.5 % vs 5.5 %). Non-carriers of the minor allele were protected against SARS-Cov-2 infection (OR, 95 %CI; 0.59, 0.42-0.82). The frequency of minor allele carriers was almost identical across asymptomatic, symptomatic, and hospitalised survivors. The rs1799945 variant did not affect disease severity and its occurrence was almost identical in patients and controls (P between 0.58 and 0.84).Conclusions: In conclusion, our results indicate that presence of the rs1800562 minor allele, which is associated with hereditary haemochromatosis (thus increased levels of plasma Fe), increases susceptibility to SARS-CoV-2.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinica Chimica Acta

ISSN

0009-8981

e-ISSN

1873-3492

Svazek periodika

538

Číslo periodika v rámci svazku

12/2022

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

211-215

Kód UT WoS článku

000923428500001

EID výsledku v databázi Scopus

2-s2.0-85145304911